Return to main library
LPP - Lipoprotein Particle Profile
Click here to download brochure.
REFERENCES & RESOURCES
1. Chandra R, Macfarlane R. Remnant Lipoprotein Density Profiling by CsBiEDTA Density Gradient Ultracentrifugation. Analytical Chemistry. 2006; 78:680-685.
2. Espinosa L, Macfarlane R, McNeal C. Method for Lipoprotein(a) Density Profiling by BiEDTA Differential Density Lipoprotein Ultracentrifugation. Analytical Chemisty. 2006; 78:438-444.
3. Nakajima K, Nakano T, Tanaka A. The oxidative modification hypothesis of atherosclerosis: the comparison of atherogenic effects on oxidized LDL and remnant lipoproteins in plasma. Clin Chim Acta. 2006; 367(1-2): 36-47.
4. Packard CJ. Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease. Curr Opin Lipidol. 2006; 17(4): 412-7.
5. Watanabe H, et al. Decreased high-density lipoprotein (HDL) particle size, prebeta-, and large HDL subspecies concentration in Finnish low-HDL families: relationships with intima-media thickness. Arterioscler Thromb Vasc Biol. 2006; 26(4): 897-902.
FREE FULL TEXT
6. Bell N, Johnson J, Donahoe E, Macfarlane R. Metal Ion Complexes of EDTA as Solutes for Density Gradient Ultracentrifugation: Influence of Metal Ions. Analytical Chemistry. 2005; 77(21): 7054-7061.
7. Capuzzi D, Carey C, Lincoff A, Morgan J. High-density Lipoprotein Subfractions and Risk of Coronary Artery Disease. Current Atherosclerosis Reports. 2004; 6(5): 359-65.
8. Marcovina SM, Koschinsky ML. Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol. 2003; 14(4): 361-6.
9. Otvos J. Why Cholesterol Measurements May be Misleading about Lipoprotein Levels and Cardiovascular Disease Risk - Clinical Applications of Lipoprotein Quantification Using NMR Spectroscopy. J Lab Med. 2002; 26(11/12): 544-550.
10. Cupples A, McNamara J, Nakajima K, Ordovas J, Schaefer E, Shah P, Wilson P. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis. 2001; 154(1): 229-236.
11. Handbook of Lipoprotein Testing, 2nd Edition, American Association of Clinical Chemistry, Inc., Washington DC, 2000.
12. Masuoka H, et al. Association of Remnant-Like Particle Cholesterol with Coronary Artery Disease in Patients with Normal Cholesterol Levels. Am Heart J. 2000; 139(2): 305-310.
13. Seman L, et al. Lipoprotein(a)-cholesterol and coronary heart disease in the Framingham Heart Study. Clinical Chemistry. 1999; 45(7): 1039-1046.
FREE FULL TEXT
14. Cantin B, Dagenais G, Despres J, Lamarche B, Moorjani S, Lupien P. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Aterioscler Thromb Vasc Biol. 1997; 17(6): 1098-1105.
FREE FULL TEXT
15. Fortmann S, Gardner C, Krauss R. Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA. 1996; 276(11): 875-881.
16. Dahlen G. Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis. 1994; 108(2): 111-126.
